The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Expansion of trial of eprenetapopt in combination with venetoclax and azacitidine in patients with TP53-mutated AML
On July 16, 2020, it was announced that the phase I trial (NCT04214860), evaluating eprenetapopt in combination with venetoclax and azacitidine in patients with TP53 mutations, was expanded and will include the addition of another cohort of patients who will be treated with eprenetapopt in combination with azacitidine as a frontline treatment. The decision to expand was based upon the results from two independent phase Ib/II clinical trials (NCT03588078 and NCT03072043).1
The lead-in safety portion of these studies demonstrated that both treatment regimens, eprenetapopt + venetoclax + azacitidine, and eprenetapopt + azacitidine, were well tolerated, and no dose-limiting toxicities were experienced. The expansion cohort will treat patients with TP53-muted AML with the triplet therapy of eprenetapopt + venetoclax + azacitidine (~ n = 30) and with the doublet therapy of eprenetapopt + azacitidine (~ n = 30) as frontline therapies. Safety and efficacy will be evaluated in both cohorts.1
Eprenetapopt/APR-2461
- A small molecule that, once converted into the active form, restores wild-type p53 conformation and function, thus reactivating mutant and inactivated p53 protein to induce apoptosis in cancer cells
- Is in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
- Received Breakthrough Therapy, orphan drug designation, and Fast Track designation from the U.S. Food and Drug Administration (FDA) for MDS
- Received orphan drug designation from the European Medicines Agency (EMA) for MDS, AML, and ovarian cancer
- A pivotal phase III trial, evaluating eprenetapopt in combination with azacitidine as a frontline treatment for patients with TP53-mutated MDS, is currently ongoing
NCT042148602–4
- Phase I trial of eprenetapopt in combination with venetoclax and azacitidine in TP53-mutant myeloid malignancies
- Doses:
- Eprenetapopt, 4.5 g/day
- Venetoclax, 400 mg/day
- Azacitidine, subcutaneously or intravenously, 75 mg/m2
- Primary outcomes: Tolerability and incidence of treatment-emergent adverse events
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content